{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-045885","form_type":"8-K","ticker":"OPRX","cik":"0001448431","company_name":"OptimizeRx Corp","filed_at":"2022-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.803337+00:00","generated_at":"2026-06-24T01:56:28.434916+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"OptimizeRx Q2 revenue up 3% to $14M; GAAP net loss $3.9M, cuts FY2022 guidance","bullets":["Revenue $14.0M (+3% YoY); gross margin improved to 64% from 59%.","GAAP net loss $3.9M ($0.21 loss per share) vs net income $0.4M in Q2 2021.","Non-GAAP net loss $0.7M ($0.04 loss per share) vs $1.8M income year ago.","Updated FY2022 revenue outlook to $62-68M (1-11% growth), citing temporary industry headwinds.","Closed EvinceMed acquisition in April; repurchased 232,745 shares under $20M buyback program."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-045885","json":"https://secwatch.observer/filing/0001213900-22-045885.json","markdown":"https://secwatch.observer/filing/0001213900-22-045885.md","text":"https://secwatch.observer/filing/0001213900-22-045885.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1448431/000121390022045885/0001213900-22-045885-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1448431/000121390022045885/ea164085-8k_optimizerx.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:56:28.434916+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}